The Australian medical community is abuzz with the emergence of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing significant results in early trials for addressing obesity. This medication https://minibookmarks.com/story21726791/retatrutide-australia-a-emerging-hope-for-weight-management